Venetoclax is a BH3 mimetic approved for treating C LL. Cancer cells are resistant to apoptosis but are "primed for death" and sustained by elevated BCL-2, which binds to pro-apoptotic proteins to hold them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction. 
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CELLULAR TARGETS
In tumor cells primed for death, pro-apoptotic proteins (e.g., BAK, BAX) are bound to anti-apoptotic proteins such as BCL-2. BH3-like proteins can interrupt this binding and promote cell death. BH3 mimetic drugs (ABT-737, Navitoclax, and Venetoclax) target this binding and induce apoptosis. Venetoclax avoids Navitoclax's adverse effects on platelets by specifically targeting BCL-2 instead of multiple BCL proteins.
EFFECTS ON TARGETS
Venetoclax sensitizes cells for apoptosis. When active pro-apoptotic proteins are already present, Venetoclax induces apoptosis as a single agent, though resistance can arise from other anti-apoptotic proteins, such as BCL-xL and MCL-1.
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